MedTrace Logo

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).

Conditions

  • High-Grade Glioma

Interventions

DRUG

CLR 131

CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Cellectar Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Jarrod Longcor · Chief Operating Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-05-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05610891 on ClinicalTrials.gov